Zydus receives USFDA approval USFDA to initiate Phase II clinical trial of ZYIL1 for Parkinson's disease
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
Studies have demonstrated that ZYIL1 is highly potent and can suppress inflammation caused by NLRP3 inflammasome activation
10+ emerging markets, Japan & ANZ transition in final phase
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
The product will be manufactured at Lupin's Pithampur facility in India
Dr. Reddy's has been awarded 'Gold Medal' status by EcoVadis
The Regional Reference Laboratory in Chennai is equipped with cutting-edge diagnostic technologies
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Announces changes in the commercial organization to incorporate Seagen and improve focus, speed and execution
Submissions based on positive data from the Phase 3 BASIS trial, which were presented this past weekend at the American Society of Hematology (ASH) Annual Meeting
Subscribe To Our Newsletter & Stay Updated